This article has been updated with a correction to the current market penetration for Cologuard. The correct figure is 1 percent, not 42 percent as originally reported.

NEW YORK (GenomeWeb) – Leerink on Monday initiated coverage of molecular diagnostics firm Exact Sciences with an Outperform rating and a 12-month $30 price target on the company's stock price.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.